RobertWatersRossMD

PubMed

• 31 citations
  A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local...
  Rana R. McKay, Amado J. Zurita, Lillian Werner, Justine Yang Bruce, Michael A. Carducci, Mark N. Stein, Elisabeth I. Heath, Arif Hussain, Hai T. Tran, Christopher Swee...> ;Journal of Clinical Oncology. 2016 Sep 27
• 26 citations
  A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
  Kevin D. Courtney, Judith Manola, Aymen Elfiky, Robert S. Ross, William Oh, Jeffrey T. Yap, Annick D. Van den Abbeele, Christopher W. Ryan, Tomasz M. Beer, Massimo Lod...> ;Clinical Genitourinary Cancer. 2015 Apr 1
• 190 citations
  Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, a...
  Toni K. Choueiri, Susanna Jacobus, Joaquim Bellmunt, Angela Qu, Leonard Joseph Appleman, Christopher P.G. Tretter, Glenn J. Bubley, Edward C. Stack, Sabina Signoretti,...> ;Journal of Clinical Oncology. 2014 Jun 20
• FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
  Guancial, E. A.,Werner, L.,Bellmunt, J.,Bamias, A.,Choueiri, T. K.,Ross, R.,Schutz, F. A.,Park, R. S.,O'Brien, R. J.,Hirsch, M. S.,Barletta, J. A.,Berman, D. M.,Lis, R...> ;Cancer Med. 2014 May 23
• 1 citations
  Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.
  Matthew D. Galsky, Wanling Xie, Mari Nakabayashi, Robert W. Ross, Fiona M. Fennessy, Clare M. Tempany, Toni K. Choueiri, Krystal Khine, Philip W. Kantoff, Mary-Ellen T...> ;Prostate Cancer and Prostatic Diseases. 2013 May 28
• 128 citations
  Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
  Antonio Jimeno, Glen J. Weiss, Wilson H. Miller, Scott N. Gettinger, Bernhard J. Eigl, Anne Lynne S Chang, Joi Dunbar, Shannon Devens, Kerrie Faia, Georgio Skliris, Je...> ;Clinical Cancer Research. 2013 May 15
• Contribution of diet and physical activity to metabolic parameters among survivors of childhood leukemia.
  Tonorezos ES, Robien K, Eshelman-Kent D, Moskowitz CS, Church TS, Ross R, Oeffinger KC> ;Cancer Causes Control. 2013-02-01
• Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
  Choueiri, T. K.,Vaishampayan, U.,Rosenberg, J. E.,Logan, T. F.,Harzstark, A. L.,Bukowski, R. M.,Rini, B. I.,Srinivas, S.,Stein, M. N.,Adams, L. M.,Ottesen, L. H.,Laubs...> ;J. Clin. Oncol.. 2013 Jan 10
• Atherogenic low density lipoprotein phenotype in long-term survivors of childhood acute lymphoblastic leukemia.
  Malhotra J, Tonorezos ES, Rozenberg M, Vega GL, Sklar CA, Chou J, Moskowitz CS, Eshelman-Kent DA, Janiszewski P, Ross R, Oeffinger KC> ;J. Lipid Res.. 2012-12-01
• 86 citations
  A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study
  Robert W. Ross, Matthew D. Galsky, Howard I. Scher, Jay Magidson, Karl Wassmann, Gwo-Shu Mary Lee, Leah Katz, Sumit K. Subudhi, Aseem Anand, Martin Fleisher, Philip W....> ;The Lancet. Oncology. 2012 Nov 1
• 45 citations
  Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
  Robert W. Ross, Matthew D. Galsky, Phil Febbo, Marc Barry, Jerome P. Richie, Wanling Xie, Fiona M. Fennessy, Rupal S. Bhatt, Julia H. Hayes, Toni K. Choueiri, Clare M....> ;Cancer. 2012 Oct 1
• 152 citations
  Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
  Toni K. Choueiri, Robert W. Ross, Susanna Jacobus, Ulka N. Vaishampayan, Evan Y. Yu, David I. Quinn, Noah M. Hahn, Thomas E. Hutson, Guru Sonpavde, Stephanie Morrissey...> ;Journal of Clinical Oncology. 2012 Feb 10
• 6 citations
  Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.
  Dipika Misra, Wanling Xie, Meredith M. Regan, Robert W. Ross, Gwo Shu Lee, Doris Germain, Philip W. Kantoff, William Oh> ;BJU International. 2011 Oct 1
• 58 citations
  Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.
  William Oh, Matthew D. Galsky, Walter M. Stadler, Sandy Srinivas, Franklin Chu, Glenn J. Bubley, J. Goddard, Joi Dunbar, Robert W. Ross> ;Urology. 2011 Sep 1
• 16 citations
  Development of Secreted Protein and Acidic and Rich in Cysteine (SPARC) Targeted Nanoparticles for the Prognostic Molecular Imaging of Metastatic Prostate Cancer.
  Stephanie Thomas, Peter Waterman, S. H. Chen, Brett Marinelli, Marc E. Seaman, Scott J. Rodig, Robert W. Ross, Lee Josephson, Ralph Weissleder, Kimberly A. Kelly> ;Journal of Nanomedicine & Nanotechnology. 2011 Aug 1
• SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
  Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin M, Oh WK, Lee GM, Kan...> ;J. Clin. Oncol.. 2011-06-20
• A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer.
  Oh WK, Galsky MD, Barry M, Fennessey F, Richie JP, Hayes JH, Bhatt RS, Taplin M, Febbo PG, Ross RW> ;J. Clin. Oncol.. 2011-05-20
• Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC).
  Riely GJ, Gettinger SN, Stoller RG, Gabrail NY, Dy GK, Weiss GJ, Tunkey C, Skliris G, Strychor S, Dunbar J, DeLucia D, Ross RW, Gray JE> ;J. Clin. Oncol.. 2011-05-20
• A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer.
  Choueiri TK, Vaishampayan UN, Yu EY, Quinn DI, Hahn NM, Hutson TE, Ross RW, Rosenberg JE, Jacobus SJ, Kantoff PW> ;J. Clin. Oncol.. 2011-03-01
• 264 citations
  Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.
  Lecia V. Sequist, Scott N. Gettinger, Neil Senzer, Renato G. Martins, Pasi A. Jänne, Rogerio Lilenbaum, Jhanelle E. Gray, A. John Iafrate, Ryohei Katayama, Nafeeza Haf...> ;Journal of Clinical Oncology. 2010 Nov 20
• 88 citations
  A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
  Dana E. Rathkopf, Bryan Y. Wong, Robert W. Ross, Aseem Anand, Erika Tanaka, Margaret M. Woo, Jing Hu, Andy Dzik-Jurasz, Wei Yang, Howard I. Scher> ;Cancer Chemotherapy and Pharmacology. 2010 Mar 9
• 16 citations
  Activity of Dutasteride Plus Ketoconazole in Castration-Refractory Prostate Cancer After Progression on Ketoconazole Alone
  Oliver Sartor, Mari Nakabayashi, Mary-Ellen Taplin, Robert W. Ross, Philip W. Kantoff, Steven P. Balk, William Oh> ;Clinical Genitourinary Cancer. 2009 Oct 1
• Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia.
  Oeffinger KC, Adams-Huet B, Victor RG, Church TS, Snell PG, Dunn AL, Eshelman-Kent DA, Ross R, Janiszewski PM, Turoff AJ, Brooks S, Vega GL> ;J. Clin. Oncol.. 2009-08-01
• Short-course androgen suppression therapy prior to brachytherapy for favorable-risk prostate cancer and the risk of all-cause mortality in men with or without preexist...
  Hayes JH, Chen M, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV> ;J. Clin. Oncol.. 2009-05-20
• Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.
  Winkfield KM, Chen M, Dosoretz DE, Salenius SA, Katin MJ, Ross R, D'Amico AV> ;J. Clin. Oncol.. 2009-05-20
• Join now to see all